Karuna is a clinical-stage drug development company targeting muscarinic cholinergic receptors for the treatment of psychosis and cognitive impairment across central nervous system (CNS) disorders, including schizophrenia and Alzheimer’s disease, as well as pain. Karuna’s lead product candidate, [KarXT] is being evaluated in a Phase 2 study in people with schizophrenia, with top-line results anticipated at the end of 2019. Karuna,
4 Likes
Found this:
And this:
"The clinical data with xanomeline significantly de-risks KarXT development moving forward by providing a clear efficacy signal in humans and long term safety data devoid of the safety issues that are associated with current antipsychotic medicines - tardive dyskinesia, metabolic dysfunction, weight gain, glucose intolerance, sedation and others. "
From:
2 Likes
Im looking forward to this drug, could be the first that works for negs and cog.
1 Like
My negative symptoms are luckily negligible, but the drug being devoid of the weight gain and other dangers appeals to me.
The aps I take cause me cognitive decline and can be measured on the cycle of depot and how well I do on the TV quiz countdown. My vocab recall and mathematics are significantly slowed by the aps.
It will be a few years yet, but taking a med that helps without the terrible side effects would be wondrous.
1 Like
I agree.
From what I hear, the problem with xanomeline is that is can cause side effects such as nausea and vomiting . KarXT hopes to negate this by activating some further receptors. Let’s hope it works.
Exciting times.
1 Like